95 related articles for article (PubMed ID: 3036500)
1. Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci.
Bryant RE; Mazza JA; Gardner EM
Eur J Clin Microbiol; 1987 Apr; 6(2):186-8. PubMed ID: 3036500
[TBL] [Abstract][Full Text] [Related]
2. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
Stratton CW; Liu C; Weeks LS
Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
[TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
Benson CA; Beaudette F; Trenholm G
J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
Machka K; Braveny I
Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
Coudron PE; Johnston JL; Archer GL
J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
[TBL] [Abstract][Full Text] [Related]
6. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
Jorgensen JH; Maher LA; Redding JS
Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients.
Kratzer C; Rabitsch W; Hirschl AM; Graninger W; Presterl E
Eur J Haematol; 2007 Nov; 79(5):405-9. PubMed ID: 17714506
[TBL] [Abstract][Full Text] [Related]
10. Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies.
Stratton CW; Weeks LS
Diagn Microbiol Infect Dis; 1990; 13(3):245-52. PubMed ID: 2166634
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of LY146032 (daptomycin), a new peptolide.
Ehlert F; Neu HC
Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
[TBL] [Abstract][Full Text] [Related]
12. LY146032: activity and resistance development in vitro.
Mouton RP; Mulders SL
J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
[TBL] [Abstract][Full Text] [Related]
13. Effect of the abscess environment on the antimicrobial activity of ciprofloxacin.
Bryant RE; Mazza JA
Am J Med; 1989 Nov; 87(5A):23S-27S. PubMed ID: 2589367
[TBL] [Abstract][Full Text] [Related]
14. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
Mohan SS; McDermott BP; Cunha BA
Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
[TBL] [Abstract][Full Text] [Related]
15. In vitro bactericidal activity of daptomycin against staphylococci.
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 2002 Mar; 49(3):467-70. PubMed ID: 11864946
[TBL] [Abstract][Full Text] [Related]
16. Activity of LY146032 and vancomycin against coagulase-negative staphylococci.
Low DE; Poon R
Eur J Clin Microbiol; 1987 Apr; 6(2):190. PubMed ID: 3595581
[No Abstract] [Full Text] [Related]
17. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci.
Andrew JH; Wale MC; Wale LJ; Greenwood D
J Antimicrob Chemother; 1987 Aug; 20(2):213-21. PubMed ID: 2822649
[TBL] [Abstract][Full Text] [Related]
18. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
Pohlod DJ; Saravolatz LD; Somerville MM
J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.
Verbist L
Antimicrob Agents Chemother; 1987 Feb; 31(2):340-2. PubMed ID: 3032099
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.
Fass RJ; Helsel VL
Antimicrob Agents Chemother; 1986 Nov; 30(5):781-4. PubMed ID: 3026240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
